Source: International Congress 2016 – COPD diagnosis and management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Wouter H. van Geffen (Leeuwarden, Netherlands), Wouter H. van Geffen, Rob Douma, Dirk-Jan Slebos, Huib Kerstjens. Bronchodilators delivered by nebuliser versus pMDI for exacerbations of COPD - A Cochrane review. Eur Respir J 2016; 48: Suppl. 60, 3690

Member's Comments

No comment yet.

Related content which might interest you: Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Compare clinical effectiveness of various types of bronchodilators in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Telehealthcare in COPD – A feasibility trial Source: International Congress 2016 – Non-inflammatory assessment of airway disorders Year: 2016 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Tele-monitoring intervention on COPD exacerbations Source: International Congress 2016 – Novel approaches for pulmonary rehabilitation in chronic lung diseases Year: 2016 Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013 Onset of action of formoterol/budesonide (F/B) Spiromax® compared with F/B Turbuhaler® in patients with COPD: A preliminary report Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016